Argenx
ARGX
#468
Rank
NZ$92.22 B
Marketcap
NZ$1,474
Share price
0.12%
Change (1 day)
37.06%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

EPS for Argenx (ARGX)

EPS in 2026 (TTM): NZ$27.23

According to Argenx 's latest financial reports the company's current EPS (TTM) is NZ$26.91. In 2025 the company made an earnings per share (EPS) of NZ$35.88 an increase over its 2024 EPS that were of NZ$23.69.

EPS history for Argenx from 2011 to 2026

Annual EPS

Year EPS Change
2026 (TTM)NZ$27.23-24.11%
2025NZ$35.8851.44%
2024NZ$23.69-369.77%
2023NZ-$8.78-60.46%
2022NZ-$22.2163.33%
2021NZ-$13.60-40.37%
2020NZ-$22.81183.47%
2019NZ-$8.05123.09%
2018NZ-$3.6154.93%
2017NZ-$2.3314.07%
2016NZ-$2.0413.05%
2015NZ-$1.80-36.34%
2014NZ-$2.84209.04%
2013NZ-$0.92-33.99%
2012NZ-$1.39185.59%
2011NZ-$0.49